Google-backed genetic-testing company 23andMe is launching its own drug development unit, and bringing on former Genentech executive to become its chief scientist and lead the company’s research and development efforts. 23andMe has collected genetic information from more than 850,000 customers worldwide from its $99 DNA spit test and more than …